Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 5/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241566 | 0.97 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL241567 | 0.97 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL12684291 | 0.97 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL6696679 | 0.88 | PREP (0.40) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL1336739 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL8337646 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL8313247 | 0.87 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL15116700 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL4795338 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL3050914 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017076187-A1 | 1,4(1,4)-DIPHENYLHEXACYCLOPHANE-12,43-DIYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | BARVIAN NICOLE C (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PRAP1, PRR12, PPIB | CHRM2 4822/4885CHRM1 4803/4885CHRM3 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.